Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO, June 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that Avidity management will be participating at the following upcoming conference:
2024年6月14日，加州生物技術公司Avidity Biosciences，Inc.（納斯達克：RNA）宣佈，該公司管理團隊將參加以下即將舉行的會議：
- TD Cowen Genetic Medicines & RNA Summit on June 20 at 8:20 a.m. PT/11:20 a.m. ET
- TD Cowen遺傳醫學和RNA峯會於6月20日上午8:20（太平洋標準時間）/上午11:20（東部標準時間）舉行。
A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at
該活動的現場網絡轉播，最新活動詳情以及存檔重播將在Avidity的網站“投資者”版塊的“活動與演示文稿”頁面提供。
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X.
關於Avidity
Avidity Biosciences，Inc.旨在通過提供一種新型的RNA治療藥物——抗體寡核苷酸結合物（AOCs），深刻改善人們的生活。Avidity正在通過其專有的AOCs革新RNA領域，這種技術通過將單克隆抗體的特異性與寡核苷酸治療的精度相結合，以解決以前存在RNA治療無法到達的靶位和疾病。利用其專有的AOC平台，Avidity展示了有史以來RNA靶向運輸進入肌肉的首次成功，並通過針對三種罕見肌肉疾病的臨床開發計劃（DM1，DMD和FSHD）領導着該領域。Avidity正在通過內部發現努力，以及關鍵合作伙伴的共同努力，擴大AOC的範圍，包括心臟病學和免疫學。Avidity總部位於加利福尼亞州聖地亞哥。有關我們的AOC平台，臨床開發管道和人員的更多信息，請訪問我們的網站，並在LinkedIn和X上與我們互動。
Investor Contact:
Geoffrey Grande, CFA
(619) 837-5014
[email protected]
投資者聯繫人：
Geoffrey Grande，CFA
（619）837-5014
[email protected]
SOURCE Avidity Biosciences, Inc.
來源：Avidity Biosciences，Inc。
譯文內容由第三人軟體翻譯。